Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Merck (NYSE:MRK) recently initiated the IDeate-Prostate01 phase 3 trial, dosing the first patient for its investigational drug ifinatamab deruxtecan, aimed at treating metastatic castration-resistant ...

Johnson & Johnson is an impeccable dividend stock with a streak of 63 consecutive dividend raises. The company's long history ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: ...

Medical Tech Stock Aethlon Medical (Nasdaq: AEMD) Treats Second Patient in Australian Hemopurifier Cancer Trial Poster Presentation Reviews the Hemopu ...

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. UBS analyst ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of ...

Like a lot of people, I’d had some squamous cell carcinomas removed from my scalp. But in June, 2024, a red splotch, about the size of my fist, appeared on ...